Clinical Trial

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to find the highest tolerable dose of PLM-102 that can be given to patients who have AML/MDS that is refractory and/or relapsed. The safety of PLM-102 will also be studied.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-04-20; most recent amendment 2026-05-18.
Trial Details
NCT Number NCT07549464
Lead Sponsor M.D. Anderson Cancer Center
Conditions Acute Myeloid Leukemia
Enrollment 12 participants
Start Date 2026-10-01
Primary Completion 2029-06-01 (estimated)
Study Completion 2031-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-20